🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ACADIA Pharmaceuticals Inc. ACAD R2K

Healthcare · Biotechnology · United States
https://www.acadia.com
Company Profile ↓
$25.92
+18.41% 1Y
Mkt Cap$4.44B
P/E11.73
P/B2.89
52W High$28.06
52W Low$20.06
Book Value$7.29
EPS (TTM)$2.21

Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 37.3%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 93.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 27.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 11.7, below the sector median of 25.9.

Healthy Margins

Maintains a net profit margin of 34.3%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.07B (+11.9% YoY); net profit $391.00M.
  • Trailing 12 Months Year-on-year growth — revenue +9.7%, earnings -81.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 27.5%, profit CAGR 93.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:27.48%
1 Year:9.70%

Compounded Profit Growth

5 Years:93.68%
1 Year:-81.80%

Stock Price Performance

1 Year:+18.41%
6 Months:-2.52%
3 Months:+17.71%
1 Month:+22.90%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 73% of range
$20.06 $28.06
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.70 · Neutral
Price Performance
1M+22.90%
3M+17.71%
6M-2.52%
1Y+18.41%
Valuation vs Sector

P/E of 11.73 is below the sector median of 25.88 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 37.3%.
  • Excellent profit margin of 34.3%.
  • Compounding revenue at 27.5% over 5 years.
  • Profit CAGR of 93.7% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
11.73
Industry PE
25.88
Forward P/E
29.03
PEG Ratio
50.86
Book Value
$7.29
Price to Book
2.89
P/S
3.30
EV/EBITDA
30.32
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
27.48%
Profit 5Y
93.68%
Revenue (YoY)
9.70%
Earnings (YoY)
-81.80%

Profitability & Returns

ROCE
8.14%
ROE
37.32%
ROA
3.69%
Profit Margin
34.30%
Op Margin
-1.72%
Gross Margin
61.58%
EPS (Latest Qtr)
$0.02
EPS (TTM)
$2.21

Balance Sheet & Liquidity

Debt/Equity
4.07
Quick Ratio
3.27
Current Ratio
3.59
Debt
$50.79M
Total Assets
$1.61B
Current Assets
$1.10B
Working Capital
$785.00M

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$4.44B
Total Revenue (TTM)
$1.10B
EBITDA
$92.71M
Free Cash Flow
$154.14M
Operating Cash Flow
$123.49M
Shares Outstanding
171.24M
Gross Margin
61.58%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ACAD ACADIA Pharmaceuticals Inc. R2K 25.92 11.73 $4.44B 0.00% 8.14% 37.32% 27.48% 93.68%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----30.48M35.58M-48.87M57.06M58.30M-62.96M83.20M94.59M-90.07M110.10M120.58M-106.55M115.22M131.61M-115.47M134.56M130.71M-118.46M165.24M211.70M-205.83M241.96M250.40M244.32M264.57M278.63M283.99M268.06M
Cost of Revenue -----------------------------------20.39M20.73M21.65M26.23M24.79M
Gross Profit --429.00K4.42M10.26M13.02M28.25M33.44M41.11M46.72M53.50M54.47M56.75M60.01M80.25M92.17M95.31M87.27M107.20M118.57M118.50M104.37M112.69M127.92M128.31M112.52M131.90M128.58M134.08M116.80M157.78M197.08M213.15M---223.93M243.83M256.99M257.76M243.27M
Operating Expenses -----------------------------------204.63M211.46M221.23M240.37M247.89M
Operating Income -50.26M-71.92M-72.40M--88.72M-68.04M-65.64M--54.82M-64.08M-61.27M--87.63M-57.09M-45.42M--89.52M-44.01M-85.90M--66.77M-43.71M-15.30M--113.02M-33.65M-30.87M--53.58M3.04M-57.78M-15.21M30.44M31.64M19.29M32.37M35.76M17.39M-4.62M
EBITDA -----------------------------------22.24M35.31M38.71M20.32M-1.62M
Interest Expense ----------------------------------------
Pretax Income -----------------------------------27.78M40.21M44.59M26.32M3.98M
Tax Provision -----------------------------------8.79M13.54M-27.18M-247.25M344.00K
Net Income -49.76M-71.32M-71.61M-78.70M-87.84M-67.44M-65.25M-68.87M-54.30M-63.27M-62.14M-65.49M-85.30M-54.94M-41.98M-53.04M-88.02M-42.14M-84.66M-66.76M-66.45M-43.87M-14.46M-43.09M-113.06M-34.01M-27.18M-41.73M-43.02M1.11M-65.18M45.80M16.55M33.39M32.77M18.99M26.67M71.78M273.57M3.64M
Diluted EPS ---------------------0.42-0.27-0.09-0.27-0.70-0.21-0.17-0.26-0.270.01-0.400.280.100.200.200.110.160.421.600.02
R&D Expense 22.77M20.48M25.81M-35.41M34.18M36.42M-39.28M46.59M53.11M-52.92M67.32M62.62M-72.64M64.30M120.08M-56.97M56.94M58.56M-128.85M75.65M81.34M-69.14M58.77M156.96M-59.68M76.23M66.61M78.27M77.95M87.83M-76.87M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 6.40M42.13M2.07M4.91M1.15M120.00K61.00K17.33M124.90M223.81M339.08M441.75M-517.24M726.44M957.80M1.07B
Cost of Revenue -------------10.17M41.64M81.84M89.00M
Gross Profit -------14.25M115.82M211.43M327.73M431.54M-507.07M684.80M875.96M982.51M
Operating Expenses -------------730.66M758.18M791.68M877.70M
Operating Income -45.47M15.09M-22.85M-20.89M-38.30M-93.23M-164.61M-272.81M-292.41M-247.44M-246.54M-286.59M--223.60M-73.38M84.28M104.81M
EBITDA --------------221.57M-67.83M100.16M116.57M
Interest Expense -----------------
Pretax Income --------------213.44M-51.04M258.07M138.90M
Tax Provision -------------2.53M10.25M31.62M-252.10M
Net Income -45.15M15.14M-22.77M-20.85M-37.95M-92.47M-164.44M-271.39M-289.40M-245.19M-235.26M-281.58M--215.97M-61.29M226.45M391.00M
Diluted EPS -1.200.39-0.44-0.38--------1.79--1.34-0.371.362.30
R&D Expense 41.59M20.58M17.31M18.79M26.72M60.60M73.87M99.28M149.19M187.16M240.38M319.13M239.41M361.57M351.62M303.25M328.80M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --38.39M32.11M108.59M189.12M325.46M221.90M561.15M384.51M540.20M783.18M782.62M-587.81M748.96M1.19B1.56B
Current Assets --------------507.94M616.12M938.32M1.06B
Cash & Equivalents 21.17M18.12M6.85M6.89M57.90M11.71M61.85M102.14M163.62M69.42M134.76M189.68M326.03M-114.85M188.66M319.59M177.69M
Inventory --------------6.64M35.82M21.95M34.67M
Receivables --------------62.20M98.27M98.74M121.46M
Total Liabilities --8.71M8.75M5.95M6.99M15.97M22.13M42.74M49.22M61.12M84.05M155.61M-187.40M317.20M454.96M336.81M
Current Liabilities --5.96M6.17M5.95M6.98M15.83M21.90M42.59M49.03M59.56M74.83M105.97M-125.63M254.25M394.87M277.11M
Long Term Debt ------------------
Total Debt --------------62.00M57.20M51.99M52.19M
Total Equity 52.99M12.11M29.69M23.36M84.98M182.13M309.49M199.76M518.41M335.29M479.08M699.13M627.01M-400.41M431.75M732.79M1.23B
Shares Outstanding --------------162.06M164.65M166.71M170.31M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -13.73M-10.70M-19.90M-21.63M----208.41M-217.76M-167.47M-151.13M-136.17M--114.03M16.70M157.72M109.84M
Investing Cash Flow 9.44M-1.06M5.98M-25.53M----261.92M92.47M-71.49M-165.84M192.51M-73.24M32.00M-30.54M-302.56M
Financing Cash Flow 1.16M470.00K13.94M98.17M---533.81M31.19M306.65M371.85M81.00M-8.20M25.13M6.84M49.88M
Capital Expenditure ---3.00K--618.00K-180.00K-2.14M-1.51M-812.00K-2.10M-1.13M-7.59M-1.12M--50.00K-523.00K-4.69M
Free Cash Flow ---19.90M-----209.91M-218.57M-169.57M-152.26M-143.75M--114.03M16.65M157.20M105.15M
Net Change in Cash --------------32.59M73.83M134.03M-142.84M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------82.2%92.7%94.5%96.7%97.7%-98.0%94.3%91.5%91.7%
Operating Margin % -710.5%35.8%-1,105.6%-425.6%-3,344.7%-77,691.7%-269,855.7%-1,574.1%-234.1%-110.6%-72.7%-64.9%--43.2%-10.1%8.8%9.8%
Net Margin % -705.5%35.9%-1,101.4%-424.9%-3,314.2%-77,062.5%-269,578.7%-1,565.9%-231.7%-109.6%-69.4%-63.7%--41.8%-8.4%23.6%36.5%
ROE % -372.7%51.0%-97.4%-24.5%-20.8%-29.9%-82.3%-52.4%-86.3%-51.2%-33.7%-44.9%--53.9%-14.2%30.9%31.9%
ROCE % -46.5%-88.1%-20.3%-21.0%-30.1%-82.3%-52.6%-87.2%-51.5%-34.8%-42.4%--48.4%-14.8%10.6%8.1%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ACAD

Yahoo Finance Wed, 15 Jul 2026

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

SAN DIEGO, July 15, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management te…

Yahoo Finance Sat, 11 Jul 2026

An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?

Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.

Yahoo Finance Sat, 11 Jul 2026

ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?

Acadia Pharmaceuticals (ACAD) has appointed Carl Segerstrom as Chief People Officer. Segerstrom is a human resources veteran with more than 25 years in biopharma leadership and is joining the executive team during an active period for the s…

Yahoo Finance Fri, 10 Jul 2026

Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?

ACADIA Pharmaceuticals stock has climbed 20.9% over the past month, and the broad valuation checks currently lean toward the shares looking inexpensive rather than stretched at recent prices. The 20.9% gain over the past month suggests inve…

Yahoo Finance Fri, 10 Jul 2026

How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors

In late June 2026, Acadia Pharmaceuticals reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of …

Yahoo Finance Fri, 10 Jul 2026

Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?

Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ACAD — Frequently Asked Questions

What is the current share price of ACADIA Pharmaceuticals Inc. (ACAD)?

As of 2026-07-15 16:51 PDT, ACADIA Pharmaceuticals Inc. (ACAD) trades at $25.92 on NasdaqGS. Its 52-week range is $20.06 to $28.06.

What is the market capitalisation of ACAD?

ACADIA Pharmaceuticals Inc. (ACAD) has a market capitalisation of $4.44B on NasdaqGS.

What is the P/E ratio of ACAD?

ACAD trades at a trailing price-to-earnings (P/E) ratio of 11.73. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.89.

What is the return on equity (ROE) of ACAD?

ACAD has a return on equity (ROE) of 37.32%. Its return on capital employed (ROCE) is 8.14%.

Is ACAD a good stock to buy?

This page provides a data-driven analysis of ACADIA Pharmaceuticals Inc. (ACAD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space